BRWD3 Inhibitors
BRWD3 inhibitors constitute a diverse class of chemicals that primarily target bromodomains and modify histone acetylation patterns, potentially influencing BRWD3's interactions and function. Bromodomain inhibitors, like JQ1 and I-BET151, specifically bind to the acetyl-lysine recognition pocket within bromodomains. This binding can impair BRWD3's ability to recognize and bind to acetylated lysines on histones or other proteins, a fundamental aspect of its protein-protein interaction modality.
Histone deacetylase inhibitors, such as VPA and SAHA, represent another segment of BRWD3 inhibitors. These compounds increase the overall acetylation levels of histones. Acetylated histones can serve as docking sites for proteins possessing bromodomains. Thus, an increase in histone acetylation might lead to a changed landscape of protein-protein interactions for BRWD3. On the other hand, compounds like GSK126 and UNC1999 inhibit the methyltransferase activity of enzymes like EZH2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 binds to the bromodomain, reducing its ability to recognize acetylated lysine, possibly affecting BRWD3's protein-protein interactions. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
By binding to the bromodomain, I-BET151 can impair BRWD3's interaction with acetylated lysines on histones or other proteins. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
I-BET762, another bromodomain inhibitor, can impede BRWD3's affinity for acetylated targets. | ||||||
(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide | 202590-98-5 | sc-501130 | 2.5 mg | $330.00 | ||
OTX015 binds bromodomains, reducing their interaction with acetylated lysine residues. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
VPA is a histone deacetylase inhibitor, increasing acetylation levels which might change the interaction landscape for BRWD3. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
As a histone deacetylase inhibitor, SAHA increases histone acetylation which can modify BRWD3's interactions. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
By inhibiting histone deacetylation, Romidepsin can affect BRWD3's recognition of histones. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat increases histone acetylation, potentially changing the binding preferences of BRWD3. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
As a histone deacetylase inhibitor, it can modulate BRWD3's protein-protein interactions by changing acetylation patterns. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
Inhibits EZH2 methyltransferase, potentially altering methylation-dependent interactions in proximity to BRWD3's targets. | ||||||